Read if you want one stock you can retire on

[Bozzie]

I seem to be real good at posting empty pictures , lol sorry

I hope some of you had PRTS , first post was 3 bucks, traded over 15 this week

Im not posting IBM, or apple . Anyone can find those stocks on their own . Im trying to post home runs and everyone in awhile we swing and miss , especially in the short run

Pred will survive this and be back

PERD's going to need to raise money or it's soon lights out..I suspect its dark already.
Either way.. it's not looking good at all unless a white rabbit shows up magically....

Sorry Bruce... No offense to you at all but its looking bad here.

 

[brucefan]

ByChris Sandburg
Posted on September 09 2020




SHARE
TWEET
SHARE
EMAIL
COMMENTS
BLOOD RACE TO IDENTIFY THE COVID-19 UNINFECTED

Cytodyn Inc. (OTCMKTS: CYDY) has a drug that could beacon the call back to work. Their drug leronlimab, appears to be turning the tide in COVID-19 patients. For those that progress to the point of a ventilator CYDY’s medicine seems to be able to quiet the cytokine storm and restore order to the immune system. Key markers in the first 4 patients indicate promising results. The first two patients on ventilators were off within two days of treatment. In re purposing this therapeutic the scientists theorized that since they were able to stop the trafficking of macrophages in the metastasis of cancer which is essentially a functional cure they could employ that same mechanism of action in COVID-19. By stopping the trafficking of macrophages to the site of infection they were able to quiet the suppression of the virus allowing the patient’s body to fight back. During a cytokine storm the virus becomes invisible to the immune system because there is basically infighting between all the immune cells trafficked there. By eliminating the threat that people will die from the disease, this one drug could restore order to the World economy.

Trump has made it clear that he wants to reopen parts of the economy by Easter, but then quickly backpedaled this weekend citing the end of April as the new date. For this to happen there needs to be a quick way to identify the infected and uninfected people. In the daily white house press briefing on March 26[SUP]th[/SUP], 2020 Dr. Debora Birx MD said

“There are antibody assays and they are by Elisa and what we are trying to do is not just do them because they can use that now but have point of care diagnostics like we have with HIV. You get a drop of blood and put it on a cassettes and then it tells you if you are positive or negative. That’s what companies are working on. Yes correct that’s the IGG to measure. Now that’s not going to be helpful in diagnosis but helpful for us to know how many asymptomatic cases there are or were.”
​

Her briefing was very descriptive and gave strong clues as to what the administration was looking to approve in the coming days to weeks. They need a mass screening with almost instantaneous results and the only way to do that is with a quick pin prick blood test that works in 2- 10 minutes. These tests have been widely used in China and are effective but they need to have FDA approval so that we don’t create and even bigger issue of identifying people as safe when in fact they are infectious. There are about 3 companies in this space and going to be a race to approval. The top 3 companies are Predictive Technologies (OTCMKTS: PRED), AYTU Bioscience (NASDAQ: AYTU) and Todos Medical (OTCMKTS:TOMDF).
SWAB VS BLOOD TEST

There is a difference between the nasal swab which is looking for active coronavirus infection versus the coronavirus antibodies that shows if a person is a carrier or has been exposed. The nasal swab determines viral infection. The top companies making these test kits are Roche Holdings (OTCMKTS: RHHBY), Lab Corp (NYSE: LH), and Thermofisher (NYSE: TMO). They use a reverse transcriptase polymerase chain reaction or RT-PCR test which can take anywhere from a few hours to a few days. In the same category of test is the 15 min test that Vice President Pence talked about before hearing from Dr. Birx. The FDA granted emergency authorization to use Abbott Laboratories (NASDAQ: ABBT) test. Abbott signaled that they could delivery up to 50,000 test kits daily but this is a far cry from meeting the overwhelming demand.

The blood test is looking for a distinct antibody which tells if a person was exposed to the virus. It’s a simple as a pin prick and then taking a micropipette to place the blood on the test kit and then waiting for a result. Even though it’s a simple test it importance cannot be stressed enough. This test could be used during a national return to work order. People that are not sick and test positive for the antibody have a relative immunity to the virus and could join the part of the return to work force.
Predictive Technologies: (OTCMKTS: PRED) Develops gene based diagnostics and companion therapeutics in the disease indications of Endometriosis, Scoliosis, and Degenerative Disc Disease, and regenerative human cell. It recently launched its Assurance AB which is a COVID-19 LgM/lgG rapid antibody test. This test is manufactured by Jiangsu Dablood Pharmaceuticals Co. Ltd. which distributed 38 million tests during the beginning of the outbreak. Current production capacity is 1.5 million units daily. The cores technology of the company is the burgeoning infertility business but they are poised to be the largest supplier in of antibody test kits. The company has about $5.0 million in current assets and a market cap of $248 million and seem well capitalized to scale up its testing business and should be the primary beneficiary of the back to work initiative which could be worth hundreds of millions in revenue this year.

AYTU Biosciences (NASDAQ: AYTU) has gotten a lot of media exposure on FOX and NBC but will it live up to expectations. AYTU is more of a therapeutics company with over 8 therapeutics and only has 1 diagnostic test for THE MiOXSYS SYSTEM which is a rapid diagnostic for diagnosing male infertility. The company has a nice therapeutics business that as of last quarter did slightly over $3.0 million in sales. The company had $5.2 million in cash at the end of 2019 but since then has done 2 at the market financings of $9.0 million and $20 million. The company is probably sitting on close to $35 million in cash. The companies share count at the end of the year was 20.7 million but the latest two financing brings the share count to 44.5 million which diluted the company over half. The cash value per share is $.79 but the company is burning close to $5.0 million quarterly. The latest financings eliminate any going concern letter and squarely position themselves for growth or potential acquisition. They recently regained NASDAQ minimum bid compliance. Their current business prospect seem tied up in the commercialization of their rapid blood test. They were anticipating 100,000 test kits last week but have not confirm

Todos Medical (OTCMKTS: TOMDF) is at heart a diagnostics company with many developed cancer screening tests. Their proprietary Total Biochemical Infrared Analysis (TBIA) quickly screen for early development of cancer using a simple blood test. Testing is their core business and they expanded into COVID-19 testing with a rapid point of care testing kit similar to AYTU. The company is using the Colloidal Gold diagnostic test. As the distribution partner for Gibraltar Brothers and Associates, TOMDF will be responsible for the obtaining FDA approval under the Emergency Use Authorization Program. Right now the company is in the validation phase and then hopes to ship 500,000 test kits in stock. The company’s supplier has the capacity to produce 300,000 test kits daily. The most interesting news is their joint venture agreement with Emerald Organic Products (OTCMKTS: EMOR) to roll out the COVID-19 test kits.

SUMMARY

In New York the health care system is close to a breaking point. They can’t get patients in and out of the hospital fast enough. There are some reports that they are getting ready to share ventilators in a controversial procedure called “splitting” which add a second set of tubes to a ventilator. The state is racing to get ventilators but tragically there is not enough supply. Leronlimab is one of the most promising drugs because within 3 days it’s demonstrated the silencing of the cytokine storm. It appears to work quicker than any other drug and is getting people off ventilators and out of the ICU. It’s important to point out that these 4 compassionate use patients are on the road to recovery. Compassionate use means that the doctors were predicting the patient’s death and were only taking palliative measures going forward. For all 4 patients to be on the road to recovery and at least 2 patients off the ventilator represents a major hope in treating the disease.
Without the existence of a non-toxic drug like leronlimab, New York State is facing and imminent overrun of the hospital system. 24,000 doses of leronlimab are available for use but the FDA desperately needs to approve the drug so it can be widely distributed. The preliminary results are so encouraging it unimaginable that the administration will sit idly by and not approve the drug while thousands of people are dying. More ventilators are not the answer, getting people off the ventilators and out of the hospital and into the home is the answer. These are trying times and the fate of our nation rests in investor’s hands who have the opportunity to shed light on the subject by rapidly bidding the price of the stock up and thereby forcing the FDA’s hand to approve the drug. The brutal reality is that many could die if capitalism fails to bring about the publicity of this drug.

Stocks like Allied Healthcare Products Inc. (NASDQ: AHPI) a maker of respiratory therapy equipment and emergency medical supplies with quarterly sales of $7.3 million and a quarterly loss of $1.5 million zoomed to a valuation of $180 million before settling down to a $68 million market cap. The markets spoke and told us the panic was real and now the market need to speak again and tell us that hope is real. If leronlimab is approved by the FDA, within 6 weeks it could be selling 100,000 vials in April. Assuming $2500 per dose this equates to $250 mil in monthly sales that ramp to 500,000 vials the following month which is $1.25 billion monthly. The current market cap is $650 million which represent a fraction to expected monthly sales.
We will be updating our subscribers with more updates. For the latest updates on Coronavirus Stocks, sign up below!
Disclosure: Insider Financial and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.

 

[brucefan]

Old article but resent to their readers with a fresh date

Think or Swim platform showing earnings will be released sept 30th

 

[daytradez]

#following.

 

[GatorHator]

I haven't been on this site since I lost thousands on PRED....I still hold it. Bought at 3.40. I did buy PRTS without knowing that Brucefan has it on his radar. i bought at 2.39 and sold at 12.32. Still own a small stake.
My 3 buys today were
PACB
CLFD
EXAS

 

[okie77]

Now . 16 cents and on its final descent. Oh well on to the next one

 

[brucefan]

8 K FILING 3 MILLION LOAN TO THE COMPANY FROM PRO PHASE LABS

https://www.otcmarkets.com/filing/h...d7NEOdV9aCsAz1MzkaHpcy4Abcj5NA7EgcerGaQDu8Ung

ProPhase Labs Engages Industry Expert to Advise on Possible Acquisition of CLIA Accredited Labs Certified for COVID-19 and Other Testing







ProPhase Labs, Inc.Wed, September 30, 2020, 5:04 PM EDT







Company Enters into Consulting Agreement and Amended and Restated Promissory Note and Security Agreement with Predictive Laboratories, Inc. to Further These Plans
DOYLESTOWN, Pennsylvania, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced its intention to explore the acquisition of one or more CLIA (Clinical Laboratory Improvement Amendment) accredited labs suitable for COVID-19 and other testing.
To assist with this process, the Company has entered into a Consulting Agreement with industry expert Predictive Laboratories, Inc. (“Predictive Labs”), pursuant to which Predictive Labs has agreed to provide certain consulting and other services to the Company, including its assistance in: (i) identifying and introducing the Company to new opportunities in the medical technology and testing fields; (ii) assisting and advising the Company in acquiring one or more CLIA accredited labs suitable for COVID-19 and other testing; (iii) obtaining new business for any such labs acquired by the Company; (iv) equipping and staffing such labs; (v) advising and assisting in the operation of such labs; and (vi) assisting the Company in validating and obtaining certification of such labs.
The Company has also entered into an Amended and Restated Promissory Note and Security Agreement (the “New Note”) with Predictive Labs, pursuant to which the Company has loaned to Predictive Labs $3.0 million (inclusive of $1.0 million in the aggregate previously loaned to Predictive Labs in July 2020 by the Company).
All compensation that may be earned by Predictive Labs under the Consulting Agreement is milestone-based and will first be applied to the acceleration and prepayment of all sums due to the Company, including but not limited to sums due pursuant to the New Note.
“While there can be no assurances that we will consummate an acquisition, I look forward to working with Predictive Labs and believe that their robust industry expertise in building and operating CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendment) accredited laboratories will prove invaluable as we evaluate opportunities in this space. We look forward to working closely with their team to pursue these exciting new business opportunities, working to create sustainable value for our shareholders over the long-term.”
About ProPhase Labs
ProPhase Labs (NASDAQ: PRPH) is a manufacturing and marketing company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand.
In addition, the Company also continues to actively pursue acquisition opportunities for other companies, businesses, technologies and products inside and outside the consumer products industry. For more information visit us at www.ProPhaseLabs.com.
About Predictive Laboratories, Inc.
Predictive Laboratories, Inc., a wholly owned molecular and genetic diagnostics company and subsidiary of Predictive Technology Group, Inc. (OTC: PRED), is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for any next-generation sequencing experiments including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies-predictivelabs.com.
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company’s potential acquisition of one or more CLIA labs and milestone payments that may become due under the Consulting Agreement. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.
Investor Relations:
Chris Tyson
Executive Vice President
MZ Group - MZ North America
(949) 491-8235
PRPH@mzgroup.us
www.mzgroup.us

 

[Bozzie]

So the AB and the 5.5 million was never anything?

Bruce this company is all over the board....Most of the time news is easily digested but this company has a major communication problem with old unresolved issues and lingering questions..Like the AB ..sham? it seems like it.

 

[brucefan]

After the financials are released, look for news flow to begin in Nov

For those of you who held never sold PRED on the big run ( that would include yours truly) , I want to share another name with you

RAFA 1.75

As you know I swing for the fences , so the upside , and risk reward are staggering . I hope some of you that got smoked in PRED ( at least for now ) will investigate this name


I will continue to update both stocks in this thread

The stock has just had a nice pulllback off the high of 2.99

http://rafarma.si/


http://rafarma.si/letter-to-shareho...quisition-by-r-d-biocogency-laboratories-inc/

[URL="https://twitter.com/rafarmapharma?s=11"]Rafarma Pharmaceuticals Inc

⁦‪@RafarmaPharma‬⁩

[/URL]

 

[brucefan]

RAFA

https://seekingalpha.com/instablog/21922151-bioresearch-alert/5506272-imminent-windfall-for-rafarma-pharmaceuticals-shareholders-confirmed-recent-approval-of

 

[brucefan]

[URL="https://twitter.com/search?q=%24RAFA&src=ctag"]$RAFA

NEWS Release 10/19 RAFARMA is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES

[/URL]
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201019:nGNXbbCJMt

 

[RapStar]

[URL="https://twitter.com/search?q=%24RAFA&src=ctag"]$RAFA

NEWS Release 10/19 RAFARMA is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES

[/URL]
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201019:nGNXbbCJMt

Thanks Bruce. Following.

 

[brucefan]

S A Advisory buy Recommendation -November 1st 2020
PREDICTIVE TECHNOLOGY GROUP, INC. (PRED~.20)

http://www.predtechgroup.com

I know what you are thinking is that we picked a super "dog" and have refused to admit it! It sure appears that way unless you remain focused with your eyes on the ball!

Our recommended price was of course higher than the current share price that has become severely tainted by its current listing on the "greys". The company is actively pursuing up listing that can be obtained either by "evil" FINRA letting them emerge from the "greys"! A merger into a listed entity or even a "SPAC"! There are many possible options that may be pursued .

The recent 10k just released a few days ago states that they remain an "on going concern" qualified by their auditor, Deloitte & Touche (top 2 auditor in USA).

The core business model remains in place, Stem cells sales, eventual marketing of their Endometriosis and infertility test kits and their "new" endeavors.

During the 3rd Q of 2020 the company had introduced Covid19 Saliva tests (Assurance VR COVID-19 RT-PCR. The viral test is intended for the qualitative detection of SARS-CoV-2 coronavirus during the acute phase of COVID-19 infection. The sample is processed and results delivered by Predictive Labs, a high-complexity CLIA lab. Assurance VR uses EUA approved Thermo Fisher Taqpath Covid -19 Combo kits for the detection of the SARS-CoV-2 virus.

Assurance VR samples are collected using EUA approved at-home saliva sample collection kit produced by Spectrum Solutions, LLC.

The actual processing in earnest began during the end of August 2020 and continues to ramp up! We have learned that one shift is able to handle the growing samples per day. The profit equals $50 per test. So 1000 tests per day would yield $50,000 profit per day.

Just do the math and realize the cash generating potential.

PRED also has a collaborative agreement with Atrin Pharmaceutical. Atrin will use PRED's genomics analysis in order to optimize patient selection for Atrin's ATRN-119 clinical trial.

http://www.atrinpharma.com

Atrin Pharma is a private biopharma pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the DNA Damage Response.

Atrin's lead product is ATRN-119, a novel, potentially best-in-class small molecule ATR inhibitor. Atrin plans to initiate a first-in-human trial for ATRN-119 in early 2021.

The partnering between Atrin and Predictive should not overlooked.

PRED is currently addressing use of Mesenchymal Stem Cells in treatment of secondary issues related to Covid-19. Management believes that utilizing regenerative medicine technology with the administration of MSCs may help mitigate underlying COVID-19 associated lung damage. Pending regulatory guidance could offer PRED another revenue stream of significance.

The current price too many might indicate a failed investment opportunity that should just be written off. We absolutely believe that would be the wrong choice! This company will thrive and prosper and our timing was affected by "bad luck"! We have now moved on from the past and look to the future for PRED shareholders & the enormous upside potential during 2021! The discounted value from the current share price of .20 is "crazy stupid"! This has all been brought on by the current "grey" market listing! This is going to change.

The assets, patents, CLIA, test kits, women's health assets, Atrin, salvia testing, management and BOD would indicate a $5.00 share price if our listing was on a major exchange.

As stem cells sales ramp up again, saliva covid-19 testing gains momentum and we finally get some meaningful sales from our women's health division revenues will turn this company from a discounted value play to rapid growth play in field of cutting edge biotechnology/testing.

If you own PRED at higher prices and most do we continues to rate PRED with a Strong Buy at currently overly depressed prices. Averaging down your purchase price is the smartest avenue to take in order to increase your profit potential.

The 9/30 10Q will be released with 2 weeks showing stem cells and saliva testing sales! Also see agreement with PRPH ( read presser).

WE REMAIN 100% CONFIDENT IN PRED

 

[brucefan]

https://www.youtube.com/watch?v=jQ6L7sWJMXk&feature=youtu.be

Where Better BeginsPredictivebiotech.cominquiries@predictivebiotech.comAiding the optimal healing environment within the body is the essence of regenerative medicine. And the notion of supplementing what already exists within the body is what makes birthing tissue the ideal source for regenerative products. Specifically, the Wharton’s jelly layer of the umbilical cord as well as placental tissue. So committed to the potential of these sources, Predictive has invested millions in perfecting the processing techniques necessary to maximize the promise of their regenerative factors. By combining scientific knowledge with proprietary processing we are able to fulfill the demand for consistent, potent human cell and tissue products (HCT/P), and establish higher standards for the field.

 

[brucefan]

[h=1]Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger[/h][h=2][/h][FONT=&quot]https://www.globenewswire.com/news-...-Retained-for-Rafarma-Biocogency-Merger.html#[FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
November 04, 2020 09:01 ET | Source: RAFARMA PHARMACEUTICALS INC


Nicosia, Cyprus, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTCRAFA) is pleased to announce that the elite Chicago auditing firm LJ Soldinger Associates (https://www.soldinger.com/) has been retained to provide auditing services for the resulting Rafarma group of companies from the Biocogency/Rafarma merger.
Ilya Spurov, Chairman of Rafarma, commented: “The reputation of LJ Soldinger Associates gives us confidence that our transition will be smooth, professional and efficient.”
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029

[/FONT]

 

[brucefan]

GlobeNewswire
​

Letter To Shareholders from Chairman Ilya Shpurov

Email Print Friendly Share
November 09, 2020 09:15 ET | Source: RAFARMA PHARMACEUTICALS INC


Nicosia, Cyprus , Nov. 09, 2020 (GLOBE NEWSWIRE) -- November 9, 2020 (GLOBE NEWSWIRE) Rafarma Pharmaceuticals, Inc. OTCRAFA) shares the following letter to shareholders from Chairman Ilya Shpurov:

“It is my pleasure to provide the following update on Rafarma’s exciting future that should greatly add to shareholder value.
Upon completion of our previously-announced audit process, Rafarma will file a Form 10 to become a fully-reporting company, with plans thereafter to uplist the company to a major exchange. Rafarma looks forward to meeting with interested institutional investors and brokerage firms as appropriate.
I am also pleased to announce that the company has recently executed a cancellation of common stock certificates totaling 5.4 million shares. These shares are being cancelled due to resolution of an error at the time of the issuance. This will reduce the issued and outstanding by 5,400,000 shares.”
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029


Related Articles

 

[brucefan]

FROM SAA ADV.

Concerning PRED
Please review this extremely positive press release found within their website. Surely 'cutting edge"
https://www.predictivebiotech.com/latest-news/


Investor's may think that we are crying "wolf", but instead we are "howling at the moon"


You must average down at current levels. There is a "wind of change in the air"


If you spend some time on their website you will see a huge amount of additional information~ "white papers", video, news and products.


yours truly


William
https://www.predictivebiotech.com/latest-news/

 

[Bozzie]

Good news, if it's news.

Average down off 17 cents on the grays..hows that going to work out...?

He's a kook..but I think you've mention that.

Hopefully this changes course.

Thanks Bruce.

 

[brucefan]

Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value
November 17 2020 - 10:56AM
InvestorsHub NewsWire

Print

​

Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value​

November 17, 2020 -- InvestorsHub NewsWire -- via BioResearch Alert --

• [h=1][FONT=&quot]Biocogency with $73 million 2019 sales recently acquired majority control and merged all operations into Rafarma Pharmaceuticals

• [/h]
• [h=1][FONT=&quot]There was no dilution to Rafarma shareholders and all operations and assets of both companies will be combined and reported under the ticker RAFA[/FONT][/h]
• [h=1][FONT=&quot]The merger increased Rafarma Pharmaceuticals 2019 revenues from $11.4 million to $84 million[/FONT][/h]
• [h=1][FONT=&quot]Elite accounting firm, L. J. Soldinger is retained to perform audited financials[/FONT][/h]
• [h=1][FONT=&quot]Wealthy international industrialist, Ilya Shpurov is now Chairman of the Board of Rafarma Pharmaceuticals[/FONT][/h]
• [FONT=&quot]With 2019 combined sales of $84 million, current market cap of $131 million, extraordinary strong growth, and share price of $1.69, market comps point to share price valuation several multiples higher than current price[/FONT]

Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.

On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.

About Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.
[h=2]About Biocogency[/h]Biocogency owns PJSC "Krasfarma",the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.
A rich historyis not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.
Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:

• Antibiotics;
• tuberculosis drugs in injectable forms;
• Blood substitutes;
• infusion solutions;
• Preparations of other pharmacological groups.

Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.
The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.
What Biocogency Adds to Rafarma

This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.

The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.

Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.

What's in it for RAFA? An Immediate Spike in Revenue and Profits

The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.

Those results are going to get an immediate shot of adrenaline.

During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.

Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.

More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.

When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.

That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.

Widening the Footprint

The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.

In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.

During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.

Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.

Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.

Conclusion
With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.
The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.



[/FONT]

 

[brucefan]

[h=1]Rafarma Inks Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia[/h][h=2][/h][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
December 01, 2020 10:53 ET | Source: RAFARMA PHARMACEUTICALS INC


Nicosia, Cyprus, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTCRAFA) has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia ([url]https://vaccineslab.com/[/URL]).

Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. For more information on the virus vaccine efforts of Vaccines Lab, see [url]https://vaccineslab.com/about-vaccinelab/[/URL].

Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.​

​

​

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029